Allspring Global Investments Holdings LLC Has $4.35 Million Stake in Phibro Animal Health Corporation $PAHC

Allspring Global Investments Holdings LLC decreased its position in Phibro Animal Health Corporation (NASDAQ:PAHC) by 46.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 116,544 shares of the company’s stock after selling 102,350 shares during the period. Allspring Global Investments Holdings LLC owned about 0.29% of Phibro Animal Health worth $4,347,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Millennium Management LLC increased its holdings in shares of Phibro Animal Health by 74.3% in the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock valued at $7,733,000 after purchasing an additional 154,281 shares during the period. Ranger Investment Management L.P. lifted its position in Phibro Animal Health by 101.1% in the 2nd quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company’s stock worth $9,143,000 after buying an additional 179,975 shares in the last quarter. Invesco Ltd. lifted its position in Phibro Animal Health by 22.5% in the 3rd quarter. Invesco Ltd. now owns 322,299 shares of the company’s stock worth $13,040,000 after buying an additional 59,226 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Phibro Animal Health by 9.6% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 301,605 shares of the company’s stock worth $12,203,000 after buying an additional 26,539 shares in the last quarter. Finally, Barclays PLC lifted its position in Phibro Animal Health by 47.4% in the 3rd quarter. Barclays PLC now owns 269,568 shares of the company’s stock worth $10,907,000 after buying an additional 86,719 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Insider Transactions at Phibro Animal Health

In related news, CEO Jack Bendheim sold 110,842 shares of the firm’s stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $48.38, for a total value of $5,362,535.96. Following the transaction, the chief executive officer directly owned 122,958 shares in the company, valued at approximately $5,948,708.04. This trade represents a 47.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last quarter, insiders have sold 316,472 shares of company stock valued at $15,265,419. Company insiders own 50.13% of the company’s stock.

Phibro Animal Health Stock Performance

PAHC opened at $55.66 on Wednesday. The company has a market cap of $2.26 billion, a PE ratio of 24.74, a price-to-earnings-growth ratio of 0.85 and a beta of 0.69. The stock has a 50-day moving average of $51.09 and a 200-day moving average of $44.10. Phibro Animal Health Corporation has a 52-week low of $16.16 and a 52-week high of $57.62. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.18. The company had revenue of $373.91 million during the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. As a group, equities research analysts forecast that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, March 25th. Shareholders of record on Wednesday, March 4th were given a dividend of $0.12 per share. The ex-dividend date of this dividend was Wednesday, March 4th. This represents a $0.48 dividend on an annualized basis and a yield of 0.9%. Phibro Animal Health’s dividend payout ratio is presently 21.33%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on PAHC. Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th. Finally, Morgan Stanley set a $49.00 price objective on Phibro Animal Health in a research report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Phibro Animal Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.50.

Phibro Animal Health Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.